Myeloproliferative Neoplasm

The FDA granted accelerated approval to pacritinib for treatment of adults with myelofibrosis and thrombocytopenia.

ASH announced the 36 recipients of the society’s 2022 Scholar Awards.

Fox Chase Cancer Center announced two faculty appointments.

Faith E. Davies, MD, has been appointed the inaugural director of Center for Blood Cancers at NYU Langone Health’s Perlmutter Cancer Center.

A randomized phase 3 trial of momelotinib for patients with pretreated myelofibrosis met all primary and key secondary endpoints, according to topline data released by the agent’s manufacturer.

Older patients with B-cell malignancies diagnosed with COVID-19 had a substantially higher risk for death than their counterparts aged 60 years or younger, according to study results published in JCO Oncology Practice.

Patients with blood cancer appeared at greater risk for severe and life-threatening COVID-19 illness than healthy individuals and did not always achieve optimal protection from vaccination, according to a registry-based study in Blood.

Healio provided comprehensive coverage of this year’s ASH Annual Meeting and Exposition.

Direct oral anticoagulant use appeared linked to high incidence of bleeding among patients with myeloproliferative neoplasms, according to study results presented at ASH Annual Meeting & Exposition.

Patients with acute leukemia or myelodysplastic syndrome in an active state experienced significantly greater COVID-19 severity but not higher mortality due to the virus, according to research presented at ASH Annual Meeting and Exposition.